Drug Profile
Research programme: rare genetic disease therapeutics - Blueprint Medicines
Alternative Names: ALK-2 targeting therapeutics - Blueprint MedicinesLatest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Blueprint Medicines
- Class Small molecules
- Mechanism of Action Activin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Fibrodysplasia ossificans progressiva
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Fibrodysplasia-ossificans-progressiva in USA
- 04 Jan 2019 Blueprint Medicines plans a phase II trial for BLU 782 in Fibrodysplasia ossificans progressive in the first half of 2020
- 01 Oct 2018 Blueprint Medicines plans to submit an IND application for BLU 782 by the end of 2018